CA3030872A1 - Traitement de la demence fronto-temporale. - Google Patents

Traitement de la demence fronto-temporale. Download PDF

Info

Publication number
CA3030872A1
CA3030872A1 CA3030872A CA3030872A CA3030872A1 CA 3030872 A1 CA3030872 A1 CA 3030872A1 CA 3030872 A CA3030872 A CA 3030872A CA 3030872 A CA3030872 A CA 3030872A CA 3030872 A1 CA3030872 A1 CA 3030872A1
Authority
CA
Canada
Prior art keywords
antibody
seq
amino acid
binding
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3030872A
Other languages
English (en)
Inventor
Sethu SANKARANARAYANAN
Ted Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexon Inc
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of CA3030872A1 publication Critical patent/CA3030872A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des méthodes de prévention, de réduction du risque de développement ou de traitement de la démence fronto-temporale (DFT) ou d'une variante de celle-ci, par l'administration d'un inhibiteur de la voie du complément.
CA3030872A 2016-07-19 2017-07-19 Traitement de la demence fronto-temporale. Abandoned CA3030872A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364013P 2016-07-19 2016-07-19
US62/364,013 2016-07-19
PCT/US2017/042846 WO2018017711A1 (fr) 2016-07-19 2017-07-19 Traitement de la démence fronto-temporale.

Publications (1)

Publication Number Publication Date
CA3030872A1 true CA3030872A1 (fr) 2018-01-25

Family

ID=60992917

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030872A Abandoned CA3030872A1 (fr) 2016-07-19 2017-07-19 Traitement de la demence fronto-temporale.

Country Status (6)

Country Link
EP (1) EP3487531A4 (fr)
AU (1) AU2017299579A1 (fr)
CA (1) CA3030872A1 (fr)
IL (1) IL264167A (fr)
SG (1) SG11201900123TA (fr)
WO (1) WO2018017711A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (fr) 2013-07-09 2015-01-15 Annexon, Inc. Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
WO2017091719A1 (fr) 2015-11-24 2017-06-01 Annexon, Inc. Fragments fab anti-complément de facteur c1q et leurs utilisations
CN108159421B (zh) * 2018-02-05 2021-05-18 苏州大学 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途
CA3118453A1 (fr) * 2018-11-02 2020-05-07 The Regents Of The University Of California Compositions et procedes de traitement d'une lesion cerebrale
US20240034775A1 (en) * 2020-05-05 2024-02-01 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Compositions and methods for treating epilepsy
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof
WO2023114763A1 (fr) 2021-12-13 2023-06-22 Annexon, Inc. Anticorps anti-facteur du complément c1q à bras de liaison uniques et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480658B2 (en) * 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2015006507A1 (fr) * 2013-07-09 2015-01-15 Annexon, Inc. Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
HUE070383T2 (hu) * 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik

Also Published As

Publication number Publication date
IL264167A (en) 2019-02-28
AU2017299579A1 (en) 2019-01-24
EP3487531A1 (fr) 2019-05-29
SG11201900123TA (en) 2019-02-27
EP3487531A4 (fr) 2020-03-25
WO2018017711A1 (fr) 2018-01-25

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
US20190161535A1 (en) Compositions and methods for treating spinal muscular atrophy
CA3030872A1 (fr) Traitement de la demence fronto-temporale.
US20240083989A1 (en) Compositions and methods for treating brain injury
EP3454902A1 (fr) Anticorps anti-facteur du complément c4/c4b et utilisations de ceux-ci
US20240034775A1 (en) Compositions and methods for treating epilepsy
CA3006092C (fr) Fragments fab anti-complement de facteur c1q et leurs utilisations
HK40083120A (en) Anti-complement factor c1q fab fragments and uses thereof
HK40005250A (en) Compositions and methods for treating spinal muscular atrophy
HK1262078A1 (en) Anti-complement factor c1q fab fragments and uses thereof
HK1262078B (en) Anti-complement factor c1q fab fragments and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230119